Pembrolizumab (Oesophageal carcinoma or HER-2-neg gastroesophageal junction adenocarcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® Page last updated: 15 July 2022 Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 839KB) Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 339KB)